This first-in-human study will evaluate the safety and tolerability of ABBV-467 (an MCL-1 Inhibitor) in adult participants with relapsed/refractory multiple myeloma
SparkCures ID | 1059 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 108 Patients |
Treatments | |
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Measurable disease defined as at least 1 of the following:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers